Hikma Pharmaceutical | HIK - Current Liabilities


Hikma Pharmaceutical reported $1.45B in Current Liabilities for its fiscal semester ending in December of 2025.





Current Liabilities Change Date
Almirall EUR 350.64M 52.12M Dec/2025
argenx SE USD 1.32B 278.28M Dec/2025
AstraZeneca USD 32.57B 1.95B Mar/2026
Autolus Therapeutics Ltd USD 63.6M 9.84M Mar/2026
Bayer EUR 33.46B 875M Mar/2026
Fresenius EUR 8.38B 1.18B Dec/2025
Genmab DKK 1.43B 686M Dec/2025
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
GRIFOLS EUR 2.12B 105M Mar/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 9.35B 307M Mar/2026
Orion EUR 798.6M 238.3M Mar/2026
Recordati EUR 1.37B 315.51M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026
UCB EUR 4.4B 470M Dec/2025